Intellia Therapeutics reported Phase 3 success for lonvo-z (lonvoguran ziclumeran) in hereditary angioedema (HAE), cutting swelling attack rates by 87% versus placebo over six months. In the 80-patient study, more than 60% of treated patients were attack-free compared with 11% on placebo. Intellia said it has initiated rolling submission steps with the FDA as it prepares for potential approval.